# A Phase 2 Study of Pembrolizumab (MK-3475) in Combination With Azacitidine in Subjects With Chemo-refractory Metastatic Colorectal Cancer

> **NCT02260440** · PHASE2 · COMPLETED · sponsor: **Anuradha Krishnamurthy** · enrollment: 31 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Azacitidine

## Key facts

- **NCT ID:** NCT02260440
- **Lead sponsor:** Anuradha Krishnamurthy
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2016-03
- **Final completion:** 2017-09
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2019-09-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02260440

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02260440, "A Phase 2 Study of Pembrolizumab (MK-3475) in Combination With Azacitidine in Subjects With Chemo-refractory Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02260440. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*